Meet Sooner With Us, Biosimilars Industry Asks FDA

Better communications between the FDA and sponsors, and more clarity from the agency on the issue of interchangeability, were among the suggestions from industry yesterday at a public meeting on the next iteration of the user fee program under the Biosimilar User Fee Act of 2017, dubbed BSUFA III.
Source: Drug Industry Daily